『Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer』のカバーアート

Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer

Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer

無料で聴く

ポッドキャストの詳細を見る
How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through first-line metastatic disease.The conversation examines pathologic complete response (pCR), residual disease management, toxicity monitoring, multidisciplinary care, and the evolving role of biomarkers in treatment personalization.Topics include:DESTINY-Breast11 and neoadjuvant T-DXd strategiesPathologic complete response (pCR) and treatment de-escalationResidual disease management after neoadjuvant therapyDESTINY-Breast05 and adjuvant T-DXd in high-risk diseaseMonitoring and managing interstitial lung disease (ILD)Patient education, supportive care, and toxicity mitigationMultidisciplinary collaboration in HER2-positive breast cancer careDESTINY-Breast09 and first-line metastatic treatment advancesT-DXd plus pertuzumab in metastatic HER2-positive diseaseFuture roles for ctDNA and biomarker-guided treatment decisionsAs HER2-directed therapies continue to evolve, clinicians are increasingly challenged to determine when to introduce the most effective treatments, how to manage long-term toxicities, and how to personalize care across the entire disease continuum.Watch more expert oncology discussions from Community Health Media and subscribe for future conversations with leading oncology experts.–Thanks for watching!Our podcasts are also available on:Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません